Picture a village in a drought. The river dries up and the villagers queue at the one house that dug a deep well. The owner becomes the most important person in the village overnight — but the price of the well is not set by the water. It is set by how long the drought lasts: when the neighbours start digging, the queue shortens, and across the river the next village never had a drought at all.
The well is Manucurist, the Paris-born plant-based nail-care brand behind the Green Flash home gel system. The queue is Inflexion, the London mid-market private equity house that in late September agreed to take 49% at a reported enterprise value of about €300 million. The structural question the Manucurist Inflexion deal poses is not whether the company is good. It is this: if a meaningful part of a valuation rests on an advantage that regulation handed over, the remaining life of that advantage is the asset’s real maturity.
In Europe the well was scarce. In the United States, where this company now grows fastest, the river never stopped flowing. The desk’s read is that €300 million is the least interesting number in the transaction; what matters is the set of rights attached to the 49%.
The Deal
Manucurist started in 1996 as a nail salon in Paris and stayed a family business. Gaëlle Lebrat-Personnaz, who had worked in luxury brands, took it over from her mother around 2016 and rebuilt it as a nail-product brand marketed on plant-derived ingredients. In 2019 it launched Green Flash, a gel polish cured at home under a lamp and removed without acetone. The brand now sells in more than 40 countries.
Inflexion, founded in London in 1999, is a European mid-market sponsor whose most visible recent result is Medik8: invested in 2021, revenue up more than fourfold in four years, majority sold to L’Oréal in June 2025 at a reported enterprise value of about €1 billion. Manucurist is the name chosen to follow it.
- Transaction: Agreed in late September 2026. Inflexion becomes the company’s first external investor with 49% at a reported enterprise value of approximately €300 million; French press reports it beat Advent and Bellinvest. Contractual terms are undisclosed.
- Nature of the sale: The advisers represented the shareholders, not the company, and the deal was structured as a minority sale. How much of the money, if any, went into the company’s treasury is not disclosed.
- Revenue (company statements): €2.5 million in 2019, €35 million in 2023, and an expected USD 119 million — roughly €100 million — this year. Profit is not disclosed.
- United States: Listed on Sephora’s US online store last autumn, with a stated plan for 185 doors at a department-store-affiliated beauty chain. The US is already the largest market and is expected to be about a third of this year’s revenue.
- Headline multiple: About 3x this year’s expected revenue. A margin in the 17% range would imply roughly 17x earnings — an estimate on an undisclosed base.
Structure Breakdown
Start with what the growth curve measures. Revenue went from €2.5 million to €35 million in four years and is projected at about €100 million this year; the inflection coincides with the 2019 launch of Green Flash. Product-level revenue is not disclosed, but on timing alone the desk suspects it is looking at the adoption curve of one product rather than a brand. If so, €300 million is a price placed on one bottle.
Then look at what was recently placed on top of it. The product’s growth predates regulation; it rode the at-home nail demand of 2020 onward. On 1 September 2025 the European Union banned a key ingredient used to cure gel polish from cosmetics, and salons could not even use stock they had already bought. Manucurist had marketed formulations free of contested ingredients before the ban — whether the banned ingredient was ever present has not been independently confirmed beyond the company’s own account. If the account holds, this was the house that dug the well before the drought. But brands operating in Europe reformulated with substitutes and relaunched in a line. A year on, being free of that ingredient is no longer a differentiator in Europe; it is the ticket to enter.
The centre of gravity has already moved. US direct-to-consumer revenue went from USD 100,000 in 2021 to USD 12 million in 2024, with USD 30 million expected for 2025. But in the US, as far as the desk can confirm, the same ingredient remains legal. In Europe, regulation cleared the field; in the US, nobody clears it. Most of this deal’s future growth sits in a market where the fight is won on advertising budgets and shelf position, not formulation — and that market already has an incumbent. Olive & June, now owned by a large consumer-goods group, reportedly beat its own expectations by more than 150% when it launched gel polish in 2024.
The channel structure sharpens the pressure. Per 2025 reports, 70% of global sales ran through the company’s own online store. Direct sales keep the distributor’s margin but carry the full cost of acquiring every customer, so rising ad prices land straight on the P&L; moving into retail relieves acquisition cost but hands a large share of revenue to the retailer. Either path compresses margin, and the purchase itself is asymmetric: the lamp kit sells once, only colours and consumables repeat. The moat deserves the same cold look. The closed system — proprietary lamp, base and top coat — is a real advantage, but the lamp was priced from €25 at launch, so switching brands costs a dinner out. The company cites 300,000-plus users and a 97% recommendation rate; both are company claims. A barrier that capital alone cannot breach has not yet been demonstrated.
Now the price. Olive & June sold for USD 240 million in total, at under 11x earnings. Medik8 fetched about 13x revenue. The market is reading this deal through the second precedent; the category it belongs to is the first. If the base case is an exit multiple below the entry multiple, every unit of return has to come from growing earnings.
Follow the money and a second motive appears. A minority sale advised on the shareholders’ side, with the primary component undisclosed, reads as a first liquidity event as much as a growth round. The founder has said she decided not to keep the business inside the family and wanted her children free to live as they choose. That makes this a succession solution as well as a financing, and a plausible trailer for an eventual full sale.
Finally, the number 49 — exactly one step short of control. The founder keeps the company; the fund holds nearly half of a several-hundred-million-euro asset without running it. The fund deploying here has typically backed companies valued at £150 million or less, so this is larger than its usual range, taken without control, at a price above the nail-category precedent. The weight of the structure does not sit in €300 million. It sits in what rights are attached to the 49%.
The Governing Logic
One thing first: the actual terms have not been made public. What follows is not a description of signed clauses but a reverse-engineering of what an architect would have had to put in the shareholders’ agreement, given the price. On that premise, the conclusion precedes the reasoning: this structure has to be weighted toward defending principal rather than toward how to sell, because the price carries no margin of safety.
Apply the nail-category precedents and the company is worth roughly €260 million on revenue and roughly €200 million on earnings; €300 million sits 14% to 54% above that range. Decompose the return and the same point appears. Assume a five-year hold, revenue compounding at 18% a year, margin rising to 20%, and an exit at 12x earnings: exit enterprise value lands around €550 million, or 1.85x invested capital and an IRR (internal rate of return — the annualised return on money deployed) of about 13%. Earnings growth adds about €480 million; multiple contraction subtracts about €230 million. There is no buy-low-sell-high in that arithmetic; a modest shortfall in growth breaks it, and in the bear case enterprise value falls to 0.62x entry. All of this is assumption-based estimation, but the direction is not in doubt.
Downside Protection: Five Locks on 49
1. Liquidation preference. The money behind 49% is estimated at about €147 million. As ordinary shares, a sale of the company at €200 million would cost the fund a third of its principal. As preferred stock returning 1x invested capital before anyone else is paid, principal is intact down to a €147 million company value — the structure survives €300 million being cut in half. The margin of safety the price did not provide is manufactured in the document, and the founder can accept it because in a good outcome the clause never fires.
2. Performance-linked equity adjustment. The seller asked €300 million on US growth the buyer has not yet seen. The way to close that gap is not to cut the price but to defer it: if, say, 2028 earnings fall short of the promised level, the fund’s ownership rises. Because 49% is one step from control, the moment the ratchet triggers, control itself can change hands. For the founder the clause turns the price tag into a report card — she keeps the high valuation on condition that she proves it — and since her majority was the premise of the deal, the adjustment would carry a cap. This is the operating point of the desk’s Proof-Deferred Pricing pattern, settled in shares rather than deferred cash.
3. Exit rights. The minority holder’s greatest risk is not loss but deadlock: a healthy company whose majority owner will not sell turns a minority stake into paper with no buyer. The fund therefore needs a drag-along (the right to force a sale of the whole company) from year five, a put or buyback obligation on the founder or the company if no sale occurs within a defined window, and a tag-along (the right to sell on the same terms whenever the founder sells). The precedent is close at hand: in the Medik8 transaction, L’Oréal bought the majority together with the right to acquire the remainder. Inflexion has watched a contractually pre-wired exit work from the inside.
4. Vetoes and ownership of the asset. A shareholder without a board majority cannot decide; it has to be able to block — budget, new borrowing, dividends, large acquisitions, executive pay. The most important item is transfer of core intellectual property. This company’s value likely rests on one formulation, and whether that formulation, the trademarks and the regulatory registration files sit in the company’s name rather than a manufacturer’s or an individual’s decides the whole deal. If they sit outside, €300 million is a price paid for a borrowed well. Vesting of ownership in the company and a qualified second manufacturing source should be conditions precedent, with a CFO appointment right and monthly reporting in the same package.
5. Risk transfer. Ownership of the formulation, regulatory compliance and the accuracy of the financials are for the seller to represent and warrant (R&W: the seller’s contractual promises about the state of the business). Ordinary breaches can be covered by warranty insurance, but that insurance does not cover known issues or product liability — and the scenario in which the brand’s safety claims return as litigation is exactly that. It belongs under a separate special indemnity, backed by 10% to 15% of the sale proceeds held with a third party for a defined period. Part of the cash the founder took out becomes collateral.
Stack the five and the sponsor’s position is legible. This is not a design built to earn 13% a year. In the upside case — US scale proven, a large strategic buyer appearing — the estimate is 3.6x invested capital and roughly a 29% IRR. That possibility is what the fund wants to buy without staking its principal on it, so the top stays open and the floor is shut. If these mechanisms are in the document, this 49% is not an equity stake; it is a downside-capped call option, and its value is set not by the €300 million figure but by whether the five locks actually made it into the agreement.
What Must Be True
1. The reported revenue is real and durable. Every revenue figure cited is something the company told the press; the desk has not seen audited financial statements. The record also deserves a second look: the 2023 target was €40 million against an actual €35 million, the 2024 forecast was €50 million, and this year’s expectation is about €100 million — a number that has to double in two years. Correcting for how kit revenue is recognised, returns, and inventory valuation across more than 127 shades, the working assumption should be that true profit sits 10% to 20% below what the headline implies. Falsifier: the first audited accounts after closing show revenue-recognition and returns adjustments that pull margin materially below the level the price implies.
2. “Clean” survives a courtroom. The company has labelled its products as carrying no allergy risk and no carcinogenic risk. Absolute language is a weapon in marketing and a target in litigation. The lamp is presented as safer for using LEDs rather than UV, yet such lamps are reported to emit in a band close to ultraviolet; the standard of proof behind these claims must be verified. This brand’s differentiation is one word, “clean”, and a single labelling enforcement action or class action in the US would damage the whole brand, not one product. Falsifier: one US regulatory action or class action over the safety claims.
3. Growth survives the end of the drought. The company makes in France and sells in America: costs in euros, a third of revenue in dollars. A weaker dollar cuts revenue and margin at once; tariffs force a price rise or a margin give-up; rising ad prices land on a DTC-heavy model; and no US regulation is coming to remove competitors. If all four move together, the desk’s judgment — not a statistic — is that the bear-case probability rises from about 25% to 35%–40%. These risks chain rather than detonate separately: US growth slows, marketing spend rises to defend it, margin falls, earnings shrink, strategic interest cools, and the exit multiple converges from the skincare dream to the nail reality below 11x earnings. At the end of that chain enterprise value drops under €200 million, or 0.62x entry, and without the locks above the principal shrinks by the same ratio — the point at which the founder wants to delay a sale and the fund wants out. Falsifier: US revenue decelerating while marketing spend rises in the first two post-closing years.
One more fuse is psychological. In an auction with three bidders, the anchor was most likely Medik8’s outcome. The UK is reported to apply the same ingredient restriction from this September, and the UK was the company’s second market as of 2023, so the tailwind may blow once more. But as Europe already showed, it stops the moment competitors change their formula. The drought ends. Whether people still queue at this well afterward is the question this deal has not yet answered.
The Architect’s Takeaway
If you were building your own deal room, the thing to borrow from this transaction is not the €300 million but the six questions behind it: When does my advantage expire? Where is the floor? How do I defer a disagreement instead of fighting it? Where is the exit door? Whose name is on the core asset? How do I hold the table without a majority? None of these depends on the size of the capital.
Give your advantage a maturity date. Manucurist’s recent tailwind came from a drought, not from its formula. Most personal advantages are the same — a tool others have not learned yet, a regulation read early, a platform algorithm understood first. They feel like skill but are mostly a head start. Write down the three advantages you hold and the months each has left before it becomes commonplace; an architect converts an advantage into a right before it expires.
Negotiate rights, not price. Split your fee in two: a minimum you receive no matter what — your liquidation preference — and a share of the upside if the project performs. If the counterparty resists a high fixed fee, lower it and take more of the upside; they save cash today and you hold a downside-capped option, the same shape as the 49% above. And when the other side claims the project will be big and you do not yet believe it, do not ask for a discount; attach a condition. If the promised number arrives, their terms hold; if not, your share grows. Someone who refuses that condition has told you something about the claim.
Draw the exit on the day you enter. Co-founding, partnerships and side ventures mostly substitute the mood of day one for a contract, then deadlock years later when one side wants to continue and the other wants out. Write three lines on the first day: who can demand a sale or wind-down after how many years; at what price the remaining party buys out the one who leaves; and whether one party selling lets the other sell on the same terms. They are written not out of distrust but so the structure outlives the relationship.
Check whose name is on your formulation, then hold the table without a majority. Is your subscriber list the platform’s or yours? Do your methods work under your own name, or only inside the organisation? A product resting on one third-party library or a channel resting on one platform’s feed is a borrowed well: secure a direct line to your audience, open a second channel, put your name on the method. Then stop trying to buy control of a small deal room. Let the operator keep the majority and hold three vetoes — transfer of the core asset, new debt, the operator’s pay — and every decision that matters passes through you. With no money at all, contribute the structure itself, paid in a performance-linked share; a handful of those is the smallest unit of a fund.
Three tasks this week: a one-page maturity table for your advantages; a rewritten rights list for one live collaboration; an ownership audit of your three core assets, moving at least one into your own name. None of it costs capital. Between the logic that moved a nine-figure stake and your next contract there is a difference of scale, not of structure.
Syndicate’s Note
Manucurist’s €300 million carries the duration of a drought that regulation created, and what protects that value is not the price but the rights attached to the 49%. Good company, tight price, outcome decided by structure. The drought will end; what remains that day is not the well but the document that records who owns it and where the exit is.
The desk is filing the governing mechanism — a temporary, regulation-made advantage capitalised as if it were a permanent moat, with the missing margin of safety rebuilt in minority terms — as a new queue entry, The Drought Premium, in the Structure Pattern Library. One case does not make a pattern; a second will.
House Verdict: WATCH. The clauses that decide this deal will not be published, so the read cannot be confirmed from the term sheet, only from the market. What would overturn it: if Manucurist’s US revenue keeps compounding through 2027 at something like its European margin, in a market that never banned the ingredient, then the moat was the brand and not the regulation, and the drought read is wrong. The verdict classifies structural learning value; it is not an investment judgment.
FAQ
What is a liquidation preference in a minority investment?
A liquidation preference is a contractual right for an investor’s class of shares to be paid a defined amount — commonly 1x the capital invested — before ordinary shareholders receive anything on a sale or liquidation. In a minority deal priced without a margin of safety, it recreates that margin inside the document rather than in the price. It costs the founder nothing in a good outcome, because it only operates when value falls.
Why did Inflexion take 49% of Manucurist rather than control?
The founder kept the majority, which was reportedly the premise of the transaction, and the sale was structured as a minority stake sold by the shareholders. The desk’s read is that the fund accepted no control in exchange for rights: a priority claim on the downside, a performance-linked adjustment, defined exit rights, and vetoes over the decisions that matter. Whether those rights were actually granted has not been disclosed.
How does the EU gel-nail ingredient ban affect Manucurist’s valuation?
The September 2025 ban removed European competitors’ existing products overnight and favoured a brand that had already marketed formulations without the contested ingredient. But competitors reformulated within a year, so in Europe the advantage has largely expired, and in the United States — the company’s largest and fastest-growing market — the ingredient remains legal as far as the desk can confirm. A valuation anchored on that tailwind is anchored on an advantage with a short remaining life.
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation. Figures are based on public reports and may be estimates.
For more structural insights and deep-dive video breakdowns, visit Structure Syndicate on YouTube.